

RESEARCH ARTICLE

Open Access



Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain

A. Orrico-Sánchez^{1*}, M. López-Lacort¹, C. Muñoz-Quiles¹, G. Sanfélix-Gimeno² and J. Díez-Domingo¹

Abstract

Background: Real-World Data (RWD) studies provide important insights in disease epidemiology, in real clinical populations, with long follow-up periods. The aim of the present study was to describe the epidemiology of schizophrenia spectrum disorders (SD) during an 8-year period in Spain.

Methods: A retrospective cohort of subjects aged 15 to 64 years was followed-up using electronic healthcare databases of the Valencia region (2008–2015). SD cases included outpatient and inpatient settings (ICD 9 codes 295.XX). Prevalence of SD was assessed. Incidence rate (IR) in the subpopulation aged between 15 and 34 years was also provided. Healthcare utilization (HCU) rates, including outpatient, specialists, hospitalizations and antipsychotic dispensations were estimated.

Results: The cohort included 3,976,071 subjects; 24,749 of them had a prevalent diagnosis of SD. The overall prevalence for SD was 6.2 per 1000 persons. SD were 76% more prevalent in men than women. IR in the subpopulation aged between 15 and 34 years was 50.25 per 100,000 persons years and was more than 2 times higher for men than for women. 83.4% of the overall outpatient visits from the cohort of patients were related to SD. The 21,095 overall hospitalizations with the SD code resulted in 286,139 days of hospitalization, with a median of 4 days (IQR: 1.6–9.2) per person-year. 93.2% of subjects diagnosed with SD were ever treated with some antipsychotic drug during the study period, and 70% of the patients were ever treated with antipsychotic polypharmacy.

Conclusions: This large population-based study using RWD provides novel and recent information SD in a southern European country. The prevalence and IR of SD showed is greater than previously published and higher in men than in women. The fact of having used a large arsenal of electronic data (including outpatient and inpatient) for 8 years may have influenced. SD represents high burden and healthcare utilization. Contrary to guidelines recommendations the majority of patients were ever treated with antipsychotic polypharmacy.

Keywords: Schizophrenia, Incidence, Prevalence, Real world data, Epidemiology, Antipsychotics

* Correspondence: orrico_ale@gva.es

¹Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Schizophrenia, a chronic and complex neuropsychiatric disorder, causes a significant impact on the quality of life of patients and their families, the social environment, and the healthcare system [1]. Schizophrenia spectrum disorders (SD) affects over 21 million people worldwide [2]; it has been estimated that approximately seven individuals per 1000 will develop SD during their lifetime [3], with onset of symptoms usually during the second or third decade [4, 5]. Disease occurrence may be associated with genetic, socio-demographic and environmental factors [3, 4, 6].

For decades it was thought that incidence of schizophrenia was consistent regardless of the geography and the time period. However, several systematic reviews have elucidated high variability of schizophrenia incidence rates among sites, ranging from 8 to 43 per 100,000 individuals [3, 6]. There is also high inconsistency in results among studies regarding the prevalence of schizophrenia, reporting up to 13-fold variation (from 0.12 to 1.6 per 100) [3, 7–9]. These discrepancies together with the scarcity of recent evidence on the incidence and prevalence published since 2005 [3, 7, 9] highlight the need for epidemiological population-based high quality studies providing incidence and prevalence estimates for different geographical settings and time periods.

Understanding resource consumption of patients with SD is a cornerstone to know the global burden of this disorder. Several studies have estimated the consumption of resources by antipsychotic treatment [10–13]. However, there is scarcity on the overall burden from a population-based cohort of subjects with SD, and these estimates are considered necessary for public health decision-making.

Antipsychotic medications are currently the main pharmacological treatment of schizophrenia [14]. However, some main challenges in the SD management remain, such as the choice among different antipsychotic classes and the patient adherence to the treatment prescribed [15]. Although many schizophrenia patients have the potential to achieve long-term remission and functional recovery under proper treatment, most patients, throughout their life, suffer relapses characterized by an exacerbation of psychosis, which often require emergency room visits and hospitalizations [1, 16–18]. Relapses may also cause subsequent refractoriness to antipsychotic treatment and loss of functional gains [16]. Additionally, and despite clinical practice guidelines for the treatment of schizophrenia recommend the use of monotherapy [12, 19, 20], a wide use of polypharmacy has been described [12].

Understanding the “epidemiological landscape” of SD requires many different types of descriptive studies [8]. Besides sociodemographic aspects, methodological differences, as for example case definition, are also

responsible for the observed discrepancies among incidence and prevalence estimations. To our knowledge, there are very few recent studies using Real-World Data (RWD) estimating the incidence and prevalence of schizophrenia [21, 22]. Most studies were not population-based [22] or were only based in hospitalization registers without considering ambulatory care information [21]. The Valencia Region (Spain) has a population of around 5 million inhabitants with universal health coverage and it counts with the Valencia health system Integrated Databases (VID), a healthcare electronic databases network gathering data from hospitalization, primary care, specialist and antipsychotic dispensations, among other [23]. The quality of VID has been shown in several publications [24–30]. The aim of this study was to describe schizophrenia incidence and prevalence, antipsychotic utilization patterns and healthcare utilization (HCU) using the healthcare databases from the Valencia Region, Spain, during an 8-year period (2008–2015).

Methods

Population-based retrospective descriptive study to estimate prevalence, incidence, and HCU for SD in the Valencia Region, Spain.

Setting and study population

The Valencia Region, Spain, has a population of approximately five million inhabitants (\approx 10% of the Spanish population) [31]. About 96% of the population is covered by the Regional Health System (RHS) [32]. The RHS is divided into 24 healthcare departments; they include 33 public hospitals, 16 of them attending psychiatric patients, and 241 healthcare districts.

The study population included all individuals aged 15 to 64 years, living in the Valencia Region and insured by the RHS at some point during January 1st, 2008, and December 31st, 2015. Subjects entered the cohort at the start of the study period, on the day of entry into the RHS, or on their fifteenth birthday, whichever occurred last. Follow-up ended when they disenrolled, turned 65 years-old, died, or at the end of the study period, whichever occurred first. Private administrative mutualism and “uninsured” individuals were excluded. For the estimation of healthcare utilization, the cohort of subjects with SD was followed from SD diagnosis until the end of the follow-up.

Real world data sources: electronic healthcare databases

We used the VID [23] which can be linked through a unique personal identification number [33]. The regional population-based administrative database (SIP) collects and updates demographic data, health services assignment and usage of the health system. The Ambulatory Care

Information System (SIA) contains medical information for each patient attended in the outpatient setting (General Practitioners, GPs, and specialist). The minimum basic data set (MBDS) collects all diagnosis and procedures from hospitalizations [34]. Diagnoses were registered using the International Classification of Diseases, Ninth Revision, Clinical Modification coding system (ICD-9-CM) [35]. Drug prescription and dispensation data are registered in the Care Provision Management (GAIA) using the Anatomical Therapeutic Chemical Classification System (ATC); for the purpose of this study, we used only dispensation data.

Case definitions and study variables

We defined an incident case of SD as the first appearance of an ICD-9-CM code related to schizophrenia spectrum disorders (295.XX) in the outpatient or inpatient (any diagnosis position) settings during the study period.

HCU among patients with SD included outpatient visits to general practitioners, visits to mental health specialists, length of hospital stay and work absences, and antipsychotic dispensations.

Sociodemographic covariates included age, sex, nationality, urban/rural residence, and social exclusion risk (SIP) [36]. Social exclusion risk classification is based on multiple aspects including unemployment, foreign in irregular situation or without resources. Rural areas were classified according to: population density (less than 100 inhabitants per Km²), urban nucleus proximity, population trend, percentage of employment in primary, secondary and tertiary sectors, and territorial structure.

We identified antipsychotic drugs through the ATC code N05A and first classified by formulation, differentiating between oral antipsychotic (OA) and long-acting injection (LAI). These two groups were sub-classified into first- and second- generation antipsychotics. Active ingredients included in each of the subgroups are described in Additional file 1. Exposure time to any treatment was defined as time from the first to the last dispensation. If only one dispensation was collected, time was estimated as date of the dispensation plus 30 days. Antipsychotic polypharmacy was defined as the overlap of two or more antipsychotic drugs dispensed simultaneously over time.

Statistical analysis

Descriptive analyses of baseline sociodemographic characteristics of overall population and population with SD were carried out, including sex, age, nationality, urban status, and social exclusion risk.

Prevalence (total number of patients diagnosed with SD divided by the total number of persons in the study population during the study period) and incidence rates (IR) of SD (total number of incident cases divided by the

total number of person-years at risk) were calculated by age, sex and overall. 95% confidence intervals (CI) were calculated by using the Poisson exact method. IR were only calculated in the subpopulation aged between 15 and 34 years. HCU rates (per subject/year) among patients diagnosed with SD were estimated. A descriptive of these results (median and interquartile range, IQR) was reported.

Antipsychotic utilization (dispensations) and polypharmacy patterns among patients with SD were also assessed. Percentage of time (Time %) during which each antipsychotic combination was used by the cohort with SD in the study period was estimated.

Analyses were developed using R Statistical Software version 3.4.3 (Foundation for Statistical Computing, Vienna, Austria).

Results

Sociodemographic characteristics of the study population

The study population included 3,976,071 subjects aged 15–64 years (50.7% men and 49.3% women) over the study period. Out of these, a total of 24,749 had a prevalent diagnosis of SD; 15,917 (64.3%) were men and 8832 (35.7%) were women. The majority of subjects with SD were Spaniards (96.4%), urban residents (97.8%), and without social exclusion risk (69.2%).

Prevalence

Age and sex specific prevalence is shown in Table 1. The overall prevalence (per 1000 persons) for SD was 6.2, having their maximum in adults aged 35–54 years old. SD were 76% more prevalent (7.9 vs. 4.5 per 1000) in men than women.

Prevalence by sex and age group is shown in Fig. 1, being higher in men than women in all age groups. The

Table 1 Prevalence (per 1000 persons) of SD by age groups and sex (2008–2015)

	Prevalence		
	Cases	Prev.	95% CI
Age (years)			
15–24	3090	3.2	(3.1–3.3)
25–34	8542	6.1	(5.9–6.2)
35–44	12,807	8.2	(8.1–8.3)
45–54	11,277	8.8	(8.6–8.9)
55–64	6260	6.2	(6.0–6.3)
15–64	24,749	6.2	(6.2–6.3)
Sex			
Male	15,917	7.9	(7.8–8.0)
Female	8832	4.5	(4.4–4.6)

Abbreviations: CI Confidence interval
Prevalence is presented per 1000 persons




Fig. 1 Change in prevalence (per 1000 persons) for schizophrenia by age group and gender (grey for females and dark grey for males) during the study period (2008–2015)

highest prevalence for males was found for the age group 35–54 years (10.6 cases per 1000 persons) while for females the prevalence was highest for the age group 45–54 years (6.9 cases per 1000 persons). Men:women ratio decreased as the age group increased. The biggest differences in sex were found in the youngest groups where prevalence in males was 2.8, and 2.4 higher than in women for the age groups 15–24 and 25–34, respectively.

Incidence

The overall IR in the subpopulation aged between 15 and 34 years (per 100,000 persons years) was 50.25 (48.86–51.67). The highest incidence was found among the age group of 25–34 years of age with an IR of 57.9 (56.0–59.9). The IR for the group of 15–24 years of age was 39.0 (37.1–41.0). Marked sex differences were found, with overall IR for men (70.64; 68.33–73.00) 2.4 times higher than for women (29.25; 27.75–30.81).

Healthcare resource utilization (HCU)

Table 2 describes the HCU by the cohort with SD. These subjects resulted in a total of 799,290 outpatient visits for any reason. Of these, 666,347 (83%) were encoded as SD, meaning a median of 3.8 (1.5–7.0) SD visits per person-year. The whole cohort of subjects with SD

Table 2 Healthcare utilization among individuals age 15–64 years diagnosed with schizophrenic disorders: 2008–2015

Healthcare utilization	N	Median (IQR)
Overall outpatient visits	799,290	4.5 (2.0–8.2)
Outpatient visits (SD)	666,347	3.8 (1.5–7.0)
^a Specialist visits	312,520	0.96 (0.0–3.6)
^b Length of hospital stay (days)	286,139	4.0 (1.6–9.2)
^c Work absences (days)	292,780	12.5 (3.4–28.8)
Antipsychotics dispensations	2,861,262	15.1 (6.6–28.5)
Antipsychotics dispensations families	N (%)	^d Subjects treated (%)
OA-2nd generation	1,696,420 (59.3)	93.4
LAI-2nd generation	576,913 (20.2)	36.0
OA-1st generation	409,121 (14.3)	33.8
LAI-1st generation	106,103 (3.7)	14.7
Other	72,705 (2.5)	13.3

Abbreviations: IQR Interquartile ratio, LAI Long-acting injection antipsychotics, OA Oral antipsychotic

Median is presented as a rate in person-year

^a Corresponding to mental health specialist visits with the ICD-9-CM code 295.XX

^b Corresponding to 21,095 hospitalizations in the cohort of patients with SD

^c Corresponding to 5445 work absences in the cohort of patients with SD

^d Subjects treated with antipsychotic drugs at some point during the study period

visited the specialist 312,520 times, corresponding to a median of 0.96 (IQR: 0.0–3.6) specialist visits per person-year. The 21,095 overall hospitalizations with the SD diagnoses code (in any diagnosis position) resulted in 286,139 days of hospital stay with a median of 4 days (IQR: 1.6–9.2) per person-year. Around 10% (2325) of the schizophrenic cohort had any work absence resulting in a total of 292,780 days off sick and a median of 12.5 (IQR: 3.4–28.8) sick days per person-year.

Utilization patterns of antipsychotics among individuals diagnosed with SD

Among the 24,749 subjects diagnosed with SD, 23,054 (93.2%) were ever treated with some antipsychotic drug during the study period. A total of 2,861,262 dispensations were associated with the treated group, which means a median of 15.1 dispensations per person-year, approximately.

Antipsychotics distribution by formulation and class is shown in Table 2. Almost all, 21,525 (93.4%) out of the 23,054 patients treated, ever used OA-2nd generation during the study period. OA-2nd generation family represented 59.3% of the total dispensations. LAI-2nd generation and OA-1st generation were the next groups of antipsychotics more frequently used with a 36 and 34% of the subjects ever treated with them, respectively. Out of the total dispensations, 20.2 and 14.3% corresponded to LAI-2nd generation and OA-1st generation, respectively. LAI-1st generation were the less commonly used by the schizophrenic cohort (14.7%).

Active ingredients included in each antipsychotic family are described in Additional file 1. The most dispensed active ingredients were risperidone, olanzapine, quetiapine, paliperidone and clozapine, representing 23.8, 12.9, 9.7, 9.7 and 7.2% of the total dispensations studied, respectively.

Out of the 23,054 subjects treated, 29.5% were on treatment with antipsychotic monotherapy, 7.2% were always on two or more antipsychotics while being under treatment (polypharmacy) and 63.3% were on both mono- and polytherapy over the study period. Polypharmacy combinations by antipsychotics formulation and class are described in Table 3. The most prevalent concomitant medications were two or more OA-2nd generation which were ever used by the 38% of the treated subjects. The second and third more frequently used combinations were OA-2nd generation + LAI-2nd generation and OA-1st generation + OA-2nd generation which were used by the 26 and 21.1% of the treated subjects, respectively. Table 3 also shows the percentage of time that each polypharmacy combination has been used during the study period. The combination of two or more OA-2nd generation was used during the longest proportion of time (16.2%), followed by OA-2nd

generation + LAI-2nd generation (12.7%). Overall, our cohort with SD was treated with different combinations of polypharmacy during 51.7% of the time.

Discussion

This large population-based study provides novel and recent information on the prevalence and incidence of schizophrenic disorders in a southern European region of 5 million inhabitants, and the healthcare resource utilization among these patients using Real World Data from outpatient (primary and specialist care) and inpatient electronic medical records during an 8-year period. In addition, antipsychotic utilization patterns among patients with SD were described focusing on polytherapy, an understudied problem in this population.

The overall prevalence of SD in the region during 2008–2015 was 6.2 per 1000 persons 15–64 years, higher in men than women (men: women rate ratio 1.75). Although differences in estimates used made difficult comparisons, our estimates were within the ranges previously published [3, 7, 8, 37], which reported a lifetime prevalence ranging from 1.6 to 12.1 per 1000 persons. However, our estimated prevalence was greater than the median lifetime prevalence published in prior reviews (4.0–5.5 per 1000) [3, 7, 8]. The differences found could be explained by the heterogeneity and complexity of the disease. In the same line, it has been previously described that the variability in prevalence also depends on the study design, geographic region, case identification methods, study quality, study dates, among others [3, 7]. Moreover, the use of a population-based design using RWD from outpatient (Primary and Specialist care) and inpatient electronic medical records in a setting with universal health coverage might also have minimized the underreporting of prevalent cases.

On the other hand, the overall IR of SD reported in the present study (50.25 per 100,000 persons-year), is higher than the published incidence, ranging from 7.7 to 43.0 per 100,000 persons; median 15.2 [3]. Given that we did not have access to historical data before the study period assessed, it is possible that some cases coded as incidents in people older than 35 years old could have been prevalent, therefore, the IR for the age groups over 35 years old might have been slightly overestimated. Thus, IR calculations were limited to population under 35 years of age. Although this limitation would be of low impact as compared with studies using claims, given that when using electronic records if a chronic diagnosis is registered this remains active lifelong or until it is resolved. Nevertheless, the estimated IR for the age groups from 15 to 34 years old can be considered highly reliable due to the onset of symptoms usually occurs during the second and third decades of life [4, 5]. Furthermore, the IR observed in these age groups are

Table 3 Antipsychotic polypharmacy combinations by treatment family in patients diagnosed with schizophrenia: 2008–2015

Polypharmacy combinations	N (% of total)	Subjects %	Time %
OA-2nd generation	18,241 (27.5)	38.1	16.2
OA-2nd generation + LAI-2nd generation	16,188 (24.4)	26.0	12.7
OA-1st generation + OA-2nd generation	10,271 (15.5)	21.1	7.9
OA-1st generation + OA-2nd generation + LAI-2nd generation	4213 (6.3)	7.5	2.4
Other ^a + OA-2nd generation	3899 (5.9)	7.9	3.1
LAI-1st generation + OA-2nd generation	3325 (5.0)	7.6	3.1
Other combinations	10,281 (15.5)	31.8	6.3

Abbreviations: OA Oral antipsychotic, LAI Long-acting injection antipsychotics

^aOther family treatments different to OA and LAI

Subjects (%), percentage of subjects ever treated with each polypharmacy combination during the study period

Time (%) represents the percentage of time, of the total study period, during which each combination has been used

For each family, two or more concomitant treatments can be included

aligned with a recent study from Denmark using population-based data from 2000 to 2012 [21]. In any case, to collect incidence data for all age groups allowed us to make a better estimate of the prevalence.

Concerning sex differences, we found a 60 and 75% higher prevalence and incidence rates in males than females, respectively. While there is a tacit understanding that sex differences in the incidence of schizophrenia are robust [3, 21, 37], several reviews did not find gender differences in prevalence [3, 8, 9, 38, 39]. From a statistical point of view these discrepancies between incidence and prevalence are unexpected [3, 8], being reasonable to observe higher prevalence in men as found in the incidence rates. Few studies have shown the expected sex differences in prevalence [22]. Some possible explanations for these differences have been suggested, as for example differences in the course of illness that have been demonstrated to be more severe in men than in women [8], implying higher utilization of health care services and, therefore, increasing the probability of detecting SD cases.

The difference in prevalence by gender was observed in all age groups, but the male: female ratio decreased as the age increased. These findings are in line with previous evidence showing that the age of onset in schizophrenia varies between males and females, where males tend to have an earlier onset [37]. Other explanations suggest that more women than men have onset later in life due to the declining of the protective effect exerted by estrogens [40] or due to psychosocial precipitating factors [41].

Despite the low prevalence of schizophrenia, the individual and societal burden associated with the disorder is very high in terms of mortality, morbidity, and economic and social costs. Population-based studies on healthcare resource utilization (HCU) are scarce and some of the most recent are focused on antipsychotic treatments patterns [10, 12, 13, 42]. In addition, previous studies on HCU for SD have shown great variability

among sites [43]. The present study provides a descriptive of the HCU, including primary care and specialist's visits, hospitalizations, work absences and antipsychotics dispensations during a recent 8-year period in a cohort of almost 25,000 patients with SD. Our cohort of patients with SD visited the General Practitioner (GP) a median of 4.5 times annually, and 3.8 of these visits (83.4%) were related to SD. Regarding hospitalizations, the median LOS of hospitalizations encoded with a SD diagnosis associated (21095) was 4 days, whereas our average LOS was 10 days (data not shown). Although these results are comparable to other European studies [43–45], the average LOS of acute psychotic episodes may be longer [46]. The fact that we considered hospitalizations for SD in any diagnosis position could have influenced these estimates. On the other hand, it has been shown a median of 12.5 work absence days per patient-year. However, these figures should be interpreted with caution as it has been estimated that three out of four patients with schizophrenia have dropped out of the job market [47].

High quality recent studies focused on the analysis of antipsychotic prescriptions patterns [10, 12, 13, 42]. Regardless this was not our main objective; we have performed a cursory description of the antipsychotic dispensation in our large cohort of patients (24749) with SD. In agreement with other literature [12, 42, 48], OA-2nd generation was the principal treatment for most of our patients. It is also important to highlight that, contrary to recommended guidelines [48] and in alignment with previous studies in other region of Spain [12], the majority of our patients (around 70%) were ever treated with antipsychotic polypharmacy.

On the other hand, an interesting result that can be found in this study is the percentage of subjects with treatment-resistant schizophrenia. This information could be estimated by reporting the proportion of subjects treated with clozapine [49]. In this study, this proportion represented the 7.2% of the total antipsychotics

dispensations accounted. This information would be very useful, since a significant amount (30–60%) of individuals with schizophrenia fail to respond to standard treatments with antipsychotics [50].

The main strength of this study is the use of the electronic healthcare databases which reflects real-life practice on a population of around 5Mill subjects with universal (96%) health coverage. The quality of these databases has been widely demonstrated in previous studies on epidemiology, treatment patterns, resource use, and drug safety and effectiveness [24–27, 30, 35, 51]. As we already pointed out, the use of multiple clinical sources of information not only from mental health services, but also from primary care, specialists, and hospitalizations confers reliability to the study. Nevertheless, some limitations should be taken into account. First of all, historical data before 2008 were not available so, as mentioned above, the IR showed for the age group of over 35 years old might be overestimated. Secondly, our polypharmacy definition could have been biased as no gaps between concomitant treatments were considered. However, as shown in Table 3, percentage of time that each polypharmacy combination was used has been described.

HCU and antipsychotics dispensations patterns data described in this study constitutes a cornerstone for future deeper population-based studies on SD including time-variations on antipsychotics prescriptions and dispensations, treatments adherence and costs.

Conclusions

This large population-based study using RWD provides novel and recent information SD in a southern European country. The prevalence and IR of SD showed is greater than previously published and higher in men than in women. The fact of having used a large arsenal of electronic data (including outpatient and inpatient) for 8 years may have influenced. SD represents high burden and HCU. Contrary to guidelines recommendations the majority of patients were ever treated with antipsychotic polypharmacy.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12888-020-02538-8>.

Additional file 1. Including information about all active ingredients included in each antipsychotic family (LAI First-Generation, OA First-Generation, LAI Second-Generation and OA Second-Generation).

Abbreviations

ATC: Anatomical Therapeutic Chemical Classification System; CI: Confidence intervals; GAIA: The Care Provision Management; HCU: Healthcare utilization; IQR: Interquartile range; IR: Incidence rate; LAI: Long-acting injection; MBDS: Minimum basic data set; OA: Oral antipsychotic; RHS: Regional Health System; RWD: Real-World Data; SIP: Population-based administrative

database; SD: Schizophrenia spectrum disorders; VID: The Valencia health system Integrated Databases

Acknowledgments

We would like to acknowledge Silvia Perez-Vilar (PharmD, PhD) for her contributions to the initial development of this project while working at FISABIO, and Professor Luis Rojo-Moreno (head of psychiatric unit at Hospital Universitario y Politécnico La Fe, Valencia, Spain) for his contribution to results interpretation.

Authors' contributions

JDD, MLL contributed to the study design. SPV submitted the protocol for ethical review and requested the data. MLL and AOS managed the data. AOS, MLL, CMQ, GSG and JDD participated in the analysis and interpretation of the data. AOS and CMQ drafted the manuscript. GSG participated in the discussion and corrections of the manuscript. All authors were involved in the critical revision of drafts and approved the final manuscript version.

Funding

This study was supported by Janssen pharmaceutical. The company had no role in the analysis or discussion of the results.

Availability of data and materials

The dataset analyzed (dissociated and aggregated) during the current study are available in this repository: <https://drive.google.com/file/d/12iBuhTowzf311Jc08HKxm7sBFVrDKpPm/view?usp=sharing>.

Ethics approval and consent to participate

The Ethics Research Committee of the Dirección General de Salud Pública/Centro Superior de Investigación en Salud Pública approved the study. Additionally, being that it is a retrospective study with 8 years of study period (2008–2015), it would have been not possible to get individual informed consent from the whole population studied (almost 4 million inhabitants). Based on Helsinki's Declaration (principle 32) and the Law of Biomedical Research in Spain (Art. 58.2), the Ethics Committee accepted the exemption.

Consent for publication

Not applicable

Competing interests

FISABIO has received research grants from various pharmaceutical companies. AOS, MLL, CMQ and JDD ever received travel grants to attend meetings sponsored by pharmaceutical companies. AOS, MLL, CMQ and JDD have been principal investigators in projects sponsored by pharmaceutical companies. JDD acted as Advisor for GSK and SPMSD.

Author details

¹Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain. ²Health Services Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain.

Received: 8 January 2019 Accepted: 9 March 2020

Published online: 05 April 2020

References

1. Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. *J Med Econ*. 2015;18(5):357–65.
2. Schizophrenia. WHOMh. WHO 2018 Available from: http://www.who.int/mental_health/management/schizophrenia/en/.
3. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol Rev*. 2008;30(1):67–76.
4. Keskinen E, Marttila A, Marttila R, Jones PB, Murray GK, Moilanen K, et al. Interaction between parental psychosis and early motor development and the risk of schizophrenia in a general population birth cohort. *Eur Psychiatry*. 2015;30(6):719–27.

5. Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: an update. *Pharmacol Ther.* 2015;153:135–47.
6. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med.* 2004;2:13.
7. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990–2013: a systematic literature review. *BMC Psychiatry.* 2015;15:193.
8. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Med.* 2005;2(5):413–33.
9. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. *Schizophr Bull.* 2018;44(6):1195–203.
10. Pilon D, Muser E, Lefebvre P, Kamstra R, Emond B, Joshi K. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. *BMC Psychiatry.* 2017;17(1):207.
11. Crivera C, DeSouza C, Kozma CM, Dirani RD, Mao L, Macfadden W. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the schizophrenia outcomes utilization relapse and clinical evaluation (SOURCE). *BMC Psychiatry.* 2011;11:168.
12. Gaviña AM, Franco JG, Aguado V, Rico G, Labad J, de Pablo J, et al. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish Province of Tarragona. *PLoS One.* 2015;10(10):e0139403.
13. Joshi K, Pan X, Wang R, Yang E, Benson C. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. *Curr Med Res Opin.* 2016;32(11):1873–81.
14. Artilles-Campelo F, MdC P-G, Caballero-Hidalgo A, Pena-Lopez MJ. Etiology of acute viral respiratory tract infections in children from Gran Canaria, the Canary Islands (Spain). *Enferm Infecc Microbiol Clin.* 2006;24(9):556–61.
15. García S, Martínez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients a systematic review. *J Clin Psychopharmacol.* 2016;36(4):355–71.
16. Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. *Prog Neuro-Psychopharmacol Biol Psychiatry.* 2015;58:1–7.
17. Voss EA, Ryan PB, Stang PE, Hough D, Alphas L. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. *Int Clin Psychopharmacol.* 2015;30(3):151–7.
18. Lafeuille M-H, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. *Am J Health Syst Pharm.* 2015;72(5):378–89.
19. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull.* 2010;36(1):71–93.
20. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol (Oxford, England).* 2011;25(5):567–620.
21. Kuhl JOG, Laursen TM, Thorup A, Nordentoft M. The incidence of schizophrenia and schizophrenia spectrum disorders in Denmark in the period 2000–2012. A register-based study. *Schizophr Res.* 2016;176(2–3):533–9.
22. Moreno-Kuestner B, Mayoral F, Navas-Campana D, Garcia-Herrera JM, Angona P, Martin C, et al. Prevalence of schizophrenia and related disorders in Malaga (Spain): results using multiple clinical databases. *Epidemiol Psychiatr Sci.* 2016;25(1):38–48.
23. García-Sempere A, Orrico-Sánchez A, Muñoz-Quiles C, Hurtado I, Peiro S, Sanfelix-Gimeno G, et al. Data resource profile: the Valencia health system integrated database (VID). *Int J Epidemiol.* 2020. <https://www.ncbi.nlm.nih.gov/pubmed/31977043>.
24. Lopez-Lacort M, Collado S, Diez-Gandia A, Diez-Domingo J. Rotavirus, vaccine failure or diagnostic error? *Vaccine.* 2016;34(48):5912–5.
25. Perez-Vilar S, Diez-Domingo J, Lopez-Lacort M, Martínez-Ubeda S, Martínez-Beneito MA. Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia region, Spain. *BMC Infect Dis.* 2015;15:92.
26. Orrico-Sánchez A, Lopez-Lacort M, Perez-Vilar S, Diez-Domingo J. Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia region, Spain. *BMC Infect Dis.* 2017;17(1):267.
27. Muñoz-Quiles C, Lopez-Lacort M, Orrico-Sánchez A, Diez-Domingo J. Impact of postherpetic neuralgia: a six year population-based analysis on people aged 50 years or older. *J Infect.* 2018;77(2):131–6.
28. Sanfelix-Genoves J, Sanfelix-Gimeno G, Peiro S, Hurtado I, Fluixa C, Fuertes A, et al. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. *Osteoporos Int.* 2013;24(3):1045–55.
29. Sanfelix-Gimeno G, Rodríguez-Bernal CL, Hurtado I, Baixáuli-Pérez C, Librero J, Peiró S. Adherence to oral anticoagulants in patients with atrial fibrillation—a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. *BMJ Open.* 2015;5(10):e007613.
30. Muñoz-Quiles C, Lopez-Lacort M, Diez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009–2014. *BMC Infect Dis.* 2018;18(1):203.
31. Valenciana G. Padrón municipal continuo Comunidad Valenciana. [Available from: <http://www.pegv.gva.es/es/demografia-y-poblacion>.
32. pública Cdsuis. Memoria de gestión. 2015.
33. Morant-Talamante N, Diez-Domingo J, Martínez-Ubeda S, Puig-Barbera J, Aleman-Sánchez S, Perez-Breva L. Herpes zoster surveillance using electronic databases in the Valencian community (Spain). *BMC Infect Dis.* 2013;13:463.
34. Ministerio de Sanidad CyBS. Hospital discharge records in the National Health System (CMBD) 2018 Available from: <https://www.mssi.gob.es/en/estadEstudios/estadisticas/cmbdhome.htm>.
35. Muñoz-Quiles C, Lopez-Lacort M, Ubeda-Sansano I, Aleman-Sánchez S, Perez-Vilar S, Puig-Barbera J, et al. Population-based analysis of bronchiolitis epidemiology in Valencia, Spain. *Pediatr Infect Dis J.* 2016;35(3):275–80.
36. Muñoz-Quiles C, Lopez-Lacort M, Ampudia-Blasco FJ, Diez-Domingo J. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009–2014. *Hum Vaccin Immunother.* 2017;13(11):2606–11.
37. Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. *Psychiatr Clin North Am.* 2007;30(3):323–38.
38. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch Gen Psychiatry.* 2007;64(1):19–28.
39. Mendrek A, Mancini-Marie A. Sex/gender differences in the brain and cognition in schizophrenia. *Neurosci Biobehav Rev.* 2016;67:57–78.
40. Seeman MV. The role of estrogen in schizophrenia. *J Psychiatry Neurosci.* 1996;21(2):123–7.
41. Chen L, Selvendra A, Stewart A, Castle D. Risk factors in early and late onset schizophrenia. *Compr Psychiatry.* 2018;80:155–62.
42. Roberts R, Neasham A, Lambrinudi C, Khan A. A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. *JRSM Open.* 2018;9(4):2054270418758570.
43. Salize HJ, McCabe R, Bullenkamp J, Hansson L, Lauber C, Martínez-Leal R, et al. Cost of treatment of schizophrenia in six European countries. *Schizophr Res.* 2009;111(1–3):70–7.
44. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, et al. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. *European psychiatric services: inputs linked to outcome domains and needs. Acta Psychiatr Scand.* 2002;105(1):42–54.
45. Hetlevik O, Solheim M, Gjesdal S. Use of GP services by patients with schizophrenia: a national cross-sectional register-based study. *BMC Health Serv Res.* 2015;15:66.
46. Millier A, Horvath M, Ma F, Koczian K, Gotze A, Toumi M. Healthcare resource use in schizophrenia, EuroSC findings. *J Market Access Health Policy.* 2017;5(1):1372027.
47. Oliva-Moreno J, Lopez-Bastida J, Osuna-Guerrero R, Montejo-Gonzalez AL, Duque-Gonzalez B. The costs of schizophrenia in Spain. *Eur J Health Econ.* 2006;7(3):182–8.
48. National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence: Guidance. Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. London: National Institute for Health and Care Excellence (UK) Copyright (c) National Collaborating Centre for Mental Health, 2014; 2014.

49. Bartoli F, Crocamo C, Di Brita C, Esposito G, Tabacchi TI, Verrengia E, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis. *J Psychiatr Res*. 2019;108:24–33.
50. Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. *BMC Psychiatry*. 2017;17(1):12.
51. Muñoz-Quiles C, López-Lacort M, Doménech-Clar R, Puig-Barberà J, Díez-Domingo J. Respiratory syncytial virus infection in adults diagnosed in Valencian region of Spain. *Rev Clin Esp*. 2016;216(9):508–10.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

